Table 3.
Clinical response to plasminogen (human)
| Patient* | Sex | Age (y) | Lesion site | Lesion assessment | ||||
|---|---|---|---|---|---|---|---|---|
| Baseline | Wk 4 | Wk 8 | Wk 12 | Wk 24 | ||||
| 1 | F | 39 | Left eye | 10 mm × 2 mm | Resolved | Resolved | Resolved | Resolved |
| Right eye | 10 mm × 2 mm | Resolved | Resolved | Resolved | Resolved | |||
| Cervix | Present | Not assessed | Not assessed | Not assessed | Not assessed | |||
| 2 | M | 35 | Left eye | 15 mm × 5 mm | Resolved | Resolved | Resolved | Resolved |
| 4 | F | 24 | Upper gingiva | Nonmeasurable† | Resolved | Resolved | Resolved | Resolved |
| Bronchus | Present | Resolved | Resolved | Resolved | Resolved | |||
| 6 | F | 37 | Left eye | Nonmeasurable | Resolved | Resolved | Resolved | Resolved |
| Right eye | Nonmeasurable | Resolved | Resolved | Resolved | Resolved | |||
| Gingiva (5 locations) | Nonmeasurable | Resolved | Resolved | Resolved | Resolved | |||
| Right nares | Present‡ | Resolved | Resolved | Resolved | Resolved | |||
| Bronchus | Present | Not assessed | Not assessed | Improved | Improved | |||
| Renal | Present | Not assessed | Not assessed | Improved | Improved | |||
| 7 | F | 24 | Cervix | Present | Not assessed | Not assessed | Not assessed | Resolved |
| 8 | F | 5 | Right eye, lower lid | 10 mm × 5 mm | 1 mm × 1 mm | Resolved | Resolved | Resolved |
| Right eye, upper lid | 15 mm × 5 mm | 5 mm × 2 mm | 5 mm × 2 mm | Nonmeasurable§ | Resolved | |||
| Vagina | Present | Not assessed | Not assessed | Not assessed | Not assessed | |||
| 9 | F | 16 | Colon | Present | Not assessed | Not assessed | Resolved | Resolved |
| Vagina | Present | Not assessed | Not assessed | Resolved | Resolved | |||
| 10 | F | 11 | Left eye | 5 mm × 3 mm | Resolved | Resolved | Resolved | Resolved |
| Colon | Present | Not assessed | Not assessed | Not assessed | Not assessed | |||
| 12 | M | 33 | Left eye | 4 mm × 4 mm | 3 mm × 2 mm | Resolved | Resolved | NA |
| Right eye | 4 mm × 4 mm | 2 mm × 2 mm | Resolved | Resolved | NA | |||
| Lower gingiva | Nonmeasurable | Improved | Improved | Improved | NA | |||
| Upper gingiva | Nonmeasurable | Improved | Improved | Improved | NA | |||
| Acne|| | Nonmeasurable | Improved | Improved | Improved | NA | |||
| Wounds/scars, hands|| | Nonmeasurable | Improved | Improved | Improved | NA | |||
| Plantar warts, feet|| | Nonmeasurable | Improved | Improved | Improved | NA | |||
| Palmar warts, hands|| | Nonmeasurable | Improved | Improved | Improved | NA | |||
| 13 | F | 33 | Left eye | 4 mm × 3 mm | 2 mm × 2 mm | 1.5 mm × 1.5 mm | Resolved | NA |
| Scar, right shoulder|| | Nonmeasurable | Unchanged | Unchanged | Improved | NA | |||
| Scar, right underarm|| | Nonmeasurable | Unchanged | Unchanged | Improved | NA | |||
| 14 | F | 42 | Left eye | Nonmeasurable | Improved | Improved | Resolved | NA |
| Right eye | Nonmeasurable | Improved | Improved | Resolved | NA | |||
| Lower gingiva | Nonmeasurable | Unchanged | Improved | Improved | NA | |||
| Upper gingiva | Nonmeasurable | Unchanged | Improved | Improved | NA | |||
| Tumors, wrists|| | Nonmeasurable | Improved | Improved | Improved | NA | |||
| Palmar warts, hands|| | Nonmeasurable | Improved | Improved | Improved | NA | |||
F, female; M, male; NA, not available.
*
Patients 3, 5, and 11 did not have lesions present at baseline.
†
Clinically visible lesions that were too small to measure using the millimeter scale were described as nonmeasurable.
‡
Lesion in the right nares was not accessed via photography; therefore, it was considered a nonvisible lesion.
§
Size of lesion decreased by 98% at week 12 to a point where it was no longer measurable using the millimeter scale.
||
Manifestations representing abnormal wound healing due to congenital plasminogen deficiency.